Skin Infection News and Research

RSS

Media examine floods' impact in Pakistan

News outlets reported on the effects of major flooding in Pakistan and described the situation on the ground.

2 Sep 2010

Scientists report frog skin contains new genera of antibiotics

Kissing a frog won't turn it into a prince except in fairy tales but frogs may be hopping toward a real world transformation into princely allies in humanity's battle with antibiotic-resistant infections that threaten millions of people worldwide. Scientists today reported that frog skin contains natural substances that could be the basis for a powerful new genre of antibiotics.

30 Aug 2010

Diarrhea, skin diseases increase among children in flood-affected areas of Pakistan: Survey

World Vision says assessments conducted over the last few days near the towns of Muzaffar Garh and Kot Addo in Punjab paint a bleak picture of the impact of the flooding. The Christian humanitarian organization says its reports from Sukkur in the Sindh Province are equally dire. Contaminated water, cramped living conditions and a lack of sanitation are contributing to a rapid increase in cases of diarrhea and skin diseases in children.

25 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

Hospital staph infection rate drops as national prevention effort steps up

The rate of drug-resistant staph hospital-acquired infections has dropped as the U.S. has stepped up prevention efforts to fight the deadly condition, The Associated Press reports. "The decline was seen in a federal study of methicillin-resistant staph, or MRSA. The bug often causes only a boil or skin infection. But researchers in the study focused on invasive cases that can become deadly, invading the bloodstream, flesh, lungs and bones. Researchers found that in nine metro areas, cases of MRSA (MUR'-suh) fell about 16 percent between 2005 and 2008.

12 Aug 2010

Pakistani officials fear cholera outbreak after massive flooding

After floods in northwest Pakistan have "already killed up to 1,200 people" and forced 2 million from their homes, authorities are now concerned about disease spread, the Associated Press reports.

2 Aug 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Antibacterial ingredient in honey identified

Sweet news for those looking for new antibiotics: A new research published in the July 2010 print edition of the FASEB Journal explains for the first time how honey kills bacteria. Specifically, the research shows that bees make a protein that they add to the honey, called defensin-1, which could one day be used to treat burns and skin infections and to develop new drugs that could combat antibiotic-resistant infections.

30 Jun 2010

IFST Advisory Statement cautions against food-borne Campylobacter infection

Campylobacter is one of the major causes of food poisoning, and the theme of this year's Food Safety Week is how to prevent illness caused by it. Campylobacter is a germ that occurs widely in the intestines of many warm-blooded animals and birds, particularly chickens and turkeys, and can be carried in animals that are used for food production and in domestic pets. In addition, it can occur in untreated water and raw milk.

5 Jun 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

NovaBay first-quarter net loss increases to $1.6 million

12 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

Women accounted for nearly 60 percent of the 39.4 million admissions to U.S. hospitals in 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

7 Apr 2010

Hospital charges for uninsured inpatient care grows by 88%

The amount that hospitals charge the uninsured for inpatient care grew by 88 percent between 1998 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The average charge for an uninsured hospital stay grew from $11,400 in 1998 to $21,400 in 2007 after adjusting for inflation.

7 Apr 2010

Astrogenetix narrows in on MRSA virulence onboard space shuttle Discovery

Astronauts on board Space Shuttle Discovery (STS-131) activated an experiment this morning as part of the ninth scientific payload for Astrogenetix, an Austin, Texas-based commercial biotech company. Astrogenetix is conducting the International Space Station National Laboratory Pathfinder Vaccine (NLP-V) missions to take advantage of the unique conditions of microgravity to uncover changes in bacteria that can be targeted to create new vaccines and therapeutics.

6 Apr 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010